In general, any submitted safety information should be of good quality (for example, GLP/GCP and OECD compliant), and contain full study reports, not summaries. The reports should provide clear, ...

In general, any submitted safety information should be of good quality (for example, GLP/GCP and OECD compliant), and contain full study reports, not summaries. The reports should provide clear, ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...

Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

Share on Pinterest Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists. Image credit: Kathryn Gamble for The Washington Post via Getty Images. Diabetes ...

Nobody could have predicted the vogue for GLP-1 drugs to promote weight loss. In the US alone, the number of patients starting GLP-1 treatments for nondiabetic purposes has increased by 700% since ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

After just a few years on the market, a new wave of GLP-1 drugs approved for weight loss have upended what we know about obesity. By now, these are household names: Mounjaro. Wegovy. Zepbound ...